外媒眼中的中国经济关键词 新华社北京12月13日电 中央经济工作会议12月10日至11日在北京举行。这是党的二十届四中全会后党中央召开的一次十分重要的会议。 新华社通过大数据工具抓取四中全会以来1169家海外主流媒体有关报道发现，"发展""增长""稳定性""贸易""投资""合作""市场""科技""人工 智能""创新"等成为海外聚焦中国经济的高频词。 "看好中国"是不少外媒的共识。它们关注中国这个全球第二大消费市场、第一大网络零售市场和第二大进口市场，关注外资企业持续加码投 资中国市场，更期待中国与各国拓展合作空间。美国《华尔街日报》网站文章说，在华西方企业正在"将中国市场视为一个创新试验场"。德国之 声电台网站说，中国显然是德国产业难以割舍的合作伙伴，而且德国企业有充分的理由这样做。西班牙《经济学家报》网站说，中国不仅向欧盟 大量出口产品和服务，而且欧盟也正成为中国企业直接投资的优先目的地。 谈及外媒关注的这些中国经济高频词，北京外国语大学国际商学院金融系主任、教授任康钰对记者说："可以看到，这些词确实是中国经济热 点问题。虽然面临诸多挑战，但中国经济在国际市场上继续保持强劲的竞争力。中国通过贸易、投资为世界 ...

Investment Rating - The report maintains an investment rating of "Outperform the Market" [4] Core Insights - The report highlights the promising data disclosure of PD-L1 ADC HLX43 by Fuhong Hanlin at WCLC 2025, indicating its potential as a superior treatment option for patients with advanced non-small cell lung cancer (NSCLC) who have failed standard therapies [2][3][18] - The report suggests that there are multiple upcoming catalysts in the sector, including academic conferences, business development (BD) opportunities, and negotiations for medical insurance and innovative drug directories [2][18] Summary by Sections Weekly New Drug Market Review - From September 1 to September 7, 2025, the top five gainers in the new drug sector were: - Saintno Pharmaceutical (+62.01%) - Chuangsheng Group (+47.26%) - Jakes Pharmaceuticals (+40.69%) - Hualing Pharmaceutical (+30.90%) - Yiming Oncology (+28.26%) - The top five decliners were: - Frontier Biopharmaceuticals (-10.47%) - Kemia (-9.09%) - Zai Lab (-5.62%) - Ascentage Pharma (-4.57%) - Yundin New Medicine (-4.56%) [1][14] Weekly Focused Stocks - The report recommends focusing on several companies with upcoming data disclosures, including Fuhong Hanlin, Baillie Tenheng, and Kangfang Biopharmaceuticals, which are expected to provide significant updates [2][18] - Potential heavyweights for overseas licensing include differentiated GLP-1 assets from companies like Zhongsheng Pharmaceutical and Gilead Sciences, as well as upgraded PD-1 products from Kangfang Biopharmaceuticals [2][18] Weekly New Drug Industry Analysis - Fuhong Hanlin's PD-L1 ADC HLX43 has shown excellent efficacy in treating NSCLC, with an overall objective response rate (ORR) of 37.0% and a disease control rate (DCR) of 87.0% in the overall NSCLC population [19][20] - The data indicates that HLX43 has the potential to expand into frontline treatment and combination therapy [2][18] New Drug Approval and Acceptance Status - This week, three new drug applications were approved, including: - Fuhong Hanlin's new drug for NSCLC - Merck's Letermovir tablets - Sanofi's Tislelizumab injection - Eleven new drug applications were accepted for review [24][25] Weekly New Drug Clinical Application Status - Twenty new drug clinical applications were approved this week, with fifty-eight applications accepted for review [27]

Group 1 - The core point of the article highlights the financing activities of Hong Kong New Drug (513780) on July 30, with a financing buy amount of 0.32 billion yuan, ranking 660th in the two markets [1] - Over the last three trading days from July 28 to July 30, Hong Kong New Drug received financing buys of 0.13 billion yuan, 0.39 billion yuan, and 0.32 billion yuan respectively [1] - On the same day, the company had no short selling activity, with both short selling and net selling at 0.00 shares [1]